Tirzepatide denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Tirzepatide — and What to Do

A prior-authorization-required denial from UnitedHealthcare means the plan will not cover tirzepatide without advance approval, and either that approval was not obtained before dispensing, or the PA request was submitted and denied. Prior authorization is a gatekeeping step, not a final coverage decision — it is fully appealable, and a denial at the PA stage triggers the same federal appeal rights as any other denial.

## Why This Denial Is Appealable

UHC's prior-authorization criteria must be clinically reasonable and applied consistently with the FDA-approved prescribing label. If your prescriber submitted the PA request with complete clinical documentation and UHC denied it, the denial must cite specific criteria your case failed to meet — and you have the right to appeal each of those criteria with evidence. If the PA was simply not submitted, the appeal process may include a retroactive PA pathway or an exception process, depending on the circumstances (emergency fill, prescriber error, plan transition).

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 (employer plans) or applicable state law, a prior-auth denial triggers full internal appeal rights. File by the deadline on the denial notice — typically 180 days.
• External review: Under ACA §2719, if the internal appeal is denied, you may request independent external review. The window is generally within approximately four months of the final internal denial.
• Expedited review: If your clinical situation is urgent, expedited internal review (and external review if needed) is available — typically decided within 72 hours.
• Concurrent review: If you are mid-course on tirzepatide and the PA is being denied for a continuing supply, request concurrent-review appeal rights, which may allow continuation of therapy during the appeal.

## Concrete Appeal Steps

1. Obtain the denial letter and identify the specific PA criteria UHC says were not met. 2. Request UHC's full prior-authorization criteria for tirzepatide — you are entitled to these. 3. With your prescriber, go through each criterion and confirm what chart documentation supports it. 4. Have your prescriber resubmit or supplement the PA with targeted documentation addressing each unmet criterion. 5. If the PA is denied again, file a formal internal appeal. 6. If denied internally, file for external review.

## Documentation to Gather

• Diagnosis confirmation: Chart notes clearly establishing the qualifying diagnosis and clinical presentation.
• Clinical severity indicators: Objective chart data relevant to UHC's PA criteria — as documented by your treating clinician.
• Prior treatment history: A complete list of prior pharmacological and lifestyle interventions with dates and documented outcomes, demonstrating that the step-therapy or treatment-history requirements are met.
• Prescriber medical-necessity letter: Addresses each PA criterion specifically, tying the criterion to a chart finding.
• FDA prescribing label: Confirms the indication and supports the clinical rationale.

## Criteria-Mapping Structure

Copy each UHC prior-authorization criterion into a table. In the right column, cite the specific chart evidence satisfying each requirement — include the date and source document (office note, lab result, pharmacy record). Your prescriber's letter should reference this table. Completeness and specificity at the PA-appeal stage dramatically reduce the likelihood of a second denial.